Inhibition of spontaneous and opiate-modified nociception by an endogenous neuropeptide with Phe-Met-Arg-Phe-NH2-like immunoreactivity.
In rats the antinociceptive actions of morphine (injected intraventricularly) or of [Met5]enkephalin-Arg6-Phe7 (YGGFMRF) (injected intrathecally) were attenuated by a pretreatment with 10 microliter of artificial cerebral spinal fluid containing 1 microM captopril/1 microM bestatin/2.5 microM Phe-Met-Arg-Phe-NH2 (FMRF-NH2) given 5 min earlier by the same route. A high molecular weight form of FMRF-NH2 purified from bovine brain attenuated the antinociceptive action of YGGFMRF. IgG, prepared from a specific FMRF-NH2 antiserum, elicited a moderate antinociception reversible by naloxone; in contrast, IgG prepared from control serum failed to change tail-flick latencies. In rats receiving morphine every 2 hr and anti-FMRF-NH2 IgG every 4 hr, the antinociceptive action was still evident after eight successive injections; in rats receiving only morphine, the antinociceptive action had disappeared after six successive injections. Morphine (1 microM) added to the perfusion fluid of the subarachnoidal spaces of rat spinal cord releases FMRF-NH2-like peptides in the perfusate.
D000818:Animals; D004361:Drug Tolerance; D004744:Enkephalin, Methionine / Q000494:pharmacology; D019835:FMRFamide; D008297:Male; D009020:Morphine / Q000494:pharmacology; D009842:Oligopeptides / Q000037:antagonists & inhibitors / Q000276:immunology / Q000502:physiology*; D010146:Pain / Q000503:physiopathology*; D051381:Rats; D013116:Spinal Cord / Q000502:physiology
D009842:Oligopeptides; D004744:Enkephalin, Methionine; D019835:FMRFamide; D009020:Morphine